Seminar "Disruptive technologies enabling patient based drug discovery", given by Ulf Nehrbass (CEO of Ksilink) on Monday 3 July at HKU - Pasteur Research Pole [fr]
The CEO of Ksilink, Dr. Ulf Nehrbass, has been invited to give a seminar on "Disruptive technologies enabling patient based drug discovery". This seminar will be held on Monday 3 July, 11:30AM, at the HKU-Pasteur Research Pole. All are welcome!
HKU-Pasteur Research Pole has invited Ulf Nehrbass, Ksilink CEO (Strasbourg, France) and former director and founder of the Institut Pasteur Korea to give a seminar on biomedical translational research and drug development.
Ksilink is a translational research centre, stemed from a Franco-German public/private partnership. The centre unites several stakeholders of biomedical research: the French National Institute of Health and Medical Research (INSERM), the University of Strasbourg, Manheim Faculty of Medicine at Heidelberg University, DKFZ (the German Cancer Research Center) and Sanofi.
Its innovative scientific approach uses cell models derived from human diseases and obtained from patients stem cells, high-throughput screening of molecules with therapeutic potential, and disruptive technologies in cell imaging associated with computational deeplearning. Ksilink directly connects basic, exploratory and applied clinical research with the goal of improving human health. It builds a professional network between excellent academics, pharmaceutical companies, SME, and biotech startups.